Home ›› 02 Feb 2023 ›› Stock
The securities regulator approved the proposal of qualified investor offer (QIO) of Al-Madina Pharmaceuticals Limited which will raise a capital worth Tk 5 crore.
The approval came Wednesday at a meeting held at the headquarters of the Bangladesh Securities and Exchange Commission (BSEC).
The drug maker will utilise the fund, which will be raised issuing shares to qualified investors, for the purpose of business expansion, repayment of bank credits and catering the expense of issue management, according to a BSEC circular.
According to the financial statement for the period July 1, 2021 to June 30, 2022, the company’s EPS was Tk 1.30 and NAV (with revaluation) per share was Tk 21.65.
The company’s NAV (without revaluation) per share for the period was Tk 12.63. Prime Bank Investment Limited will act as the issue manager of the QIO process.
